Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Free PMC article
Full text links

Actions

Case Reports
.2021 Mar 17;4(3):176-179.
doi: 10.1002/iju5.12274. eCollection 2021 May.

First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion

Affiliations
Case Reports

First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion

Kazunori Shojo et al. IJU Case Rep..

Abstract

Introduction: Ductal adenocarcinoma of the prostate is a rare prostate cancer variant and associated with higher stage and greater risk of mortality. Optimal systemic therapy for metastatic ductal adenocarcinoma is not known.

Case presentation: A 67-year-old man presented with ductal adenocarcinoma of the prostate accompanied by multiple lung metastases and advanced bone metastases. We performed channel transurethral resection of the prostate and confirmed the diagnosis of ductal adenocarcinoma of the prostate. DNA sequencing identified a TP53 somatic point mutation (p.Gly245Ser) as the pathogenic variant. Furthermore, a homozygous deletion was observed in mitogen-activated protein kinase kinase kinase 1. The patient received enzalutamide but deceased 5 months after presenting to our institution.

Conclusion: To our knowledge, this is the first report of ductal adenocarcinoma of the prostate with a mitogen-activated protein kinase kinase kinase 1 homozygous deletion. Accumulation of whole-exome sequencing data is expected to inform future advances in therapy development.

Keywords: MAP3K1; TP53; ductal adenocarcinoma of the prostate; next‐generation sequencing; prostate cancer.

© 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
(a) HE staining showing the papillary architecture, with tall, pseudostratified, columnar epithelial cells arranged over fibrovascular cores at initial diagnosis. (b) HE staining showing the papillary architecture. Nuclear irregularities are evident. (c) Androgen receptor staining of tumor cells showing partial positive staining. (d) Immunohistochemical analysis of tumor cells for PSA showing negative staining. (e) Tumor cells stained with chromogranin showing absence of stain uptake. (f) Tumor cells stained with synaptophysin showing absence of stain uptake. (g) Tumor cells stained with Ki‐67, showing a high labeling index. (h) Immunohistochemical analysis of tumor cells for MAP3K1 showing reduced staining suggesting the loss of the expression at the protein level. (i) Immunohistochemical analysis of tumor cells for TP53 showing diffuse nuclear positivity.
Fig. 2
Fig. 2
Computed tomography and magnetic resonance imaging showed multiple lung metastases and advanced bone metastases.
Fig. 3
Fig. 3
(a) Copy number plot showing the MAP3K1 homozygous deletion, (b) Kaplan–Meier curve reflecting recurrence‐free survival for MAP3K1 LOH‐negative versus. MAP3K1 LOH‐positive patients with prostate cancer.
See this image and copyright information in PMC

References

    1. Melicow MM, Pachter MR. Endometrial carcinoma of prostatic utricle (uterus masculinus). Cancer 1967; 20: 1715–22. - PubMed
    1. Zhou M. High‐grade prostatic intraepithelial neoplasia, PIN‐like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Mod. Pathol. 2018; 31: S71–S79. - PubMed
    1. Meeks JJ, Zhao LC, Cashy J, Kundu S. Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program. BJU Int. 2012; 109: 831–4. - PubMed
    1. Lawrence MG, Porter LH, Clouston D et al. Knowing what's growing: Why ductal and intraductal prostate cancer matter. Sci. Transl. Med. 2020; 12: eaaz0152. - PubMed
    1. Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology 2012; 60: 59–74. - PubMed

Publication types

LinkOut - more resources

Full text links
Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp